

Ayumi Sugiura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/204398/publications.pdf>

Version: 2024-02-01

11
papers

106
citations

1478505

6
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

119
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 280.	2.0	3
2	Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. <i>PLoS ONE</i> , 2021, 16, e0249435.	2.5	1
3	Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals. <i>Hepatology Research</i> , 2021, 51, 758-766.	3.4	3
4	Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. <i>Cancers</i> , 2021, 13, 3267.	3.7	6
5	Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1750-1755.	1.7	3
6	aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. <i>Hepatology Research</i> , 2021, 51, 933-942.	3.4	15
7	Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project. <i>PLoS ONE</i> , 2021, 16, e0256711.	2.5	2
8	Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1208-1214.	2.8	17
9	Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. <i>Biomedicines</i> , 2020, 8, 74.	3.2	11
10	Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1236-1243.	3.4	24
11	Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1462-1471.	2.0	21